Research Phase

 
News Articles for Research Phase top ^
SOLANA BEACH, Calif., April 22, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) , a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the initiation of its Phase 3 clinical trial investigating the use of EVK-001, a novel metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Sign-up for Evoke Pharma Initiates Phase 3 Clinical Trial of EVK-001 for Treatment of Gastroparesis investment picks
VANCOUVER, British Columbia, May 21, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that recent advances in its clinical programs were presented at the 17 th Annual Meeting of the American Society of Gene and Cell Therapy, which is taking place in in Washington, DC, May 21 to 24.
Sign-up for Tekmira Presents Positive Interim Results on Phase I/II Clinical Programs investment picks
SOUTH SAN FRANCISCO, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that enrollment has begun in a Phase 3 study to evaluate the safety and efficacy of andexanet alfa, the Company's investigational recombinant Factor Xa inhibitor reversal agent, with Bayer HealthCare and Janssen Pharmaceuticals Inc.'s Factor Xa inhibitor XARELTO ® (rivaroxaban). Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class agent to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are experiencing a major bleeding episode or who require emergency surgery.
Sign-up for Portola Pharmaceuticals Begins Enrollment in Phase 3 Study of FDA-Designated Breakthrough Therapy Andexanet Alfa and Factor Xa Inhibitor XARELTO(R) investment picks
NATICK, Mass., April 24, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) , a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in patients with advanced gynecologic malignancies including cervical, ovarian and uterine carcinomas.
Sign-up for Phase 2 Study of Selinexor (KPT-330) Initiated by Karyopharm in Patients With Advanced Gynecologic Malignancies (SIGN Study) investment picks
- Top-line Efficacy Data Expected in 3Q14 - NDA filing expected in 2H15 SALT LAKE CITY, April 29, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN) , a specialty pharmaceutical company, today announced that the Company has completed enrollment of its Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study ( http://clinicaltrials.gov/show/NCT02081300 ). The trial is designed to evaluate the safety and efficacy of LPCN 1021, oral testosterone undecanoate ("TU"), in hypogonadal men with low testosterone ("Low T"). The Company expects top-line efficacy data for the trial to be available in the third quarter of 2014, with a New Drug Application ("NDA") filing with the U.S. Food and Drug Administration ("FDA") anticipated in the second half of 2015.
Sign-up for Lipocine Announces Completion of Enrollment in its SOAR Phase 3 Study for Oral Testosterone Replacement Therapy investment picks
- Dosing Initiated in Phase 1 Study to Evaluate the Safety, Tolerability and Antiviral Activity of ACH-3422, NS5B Uridine-Analog Nucleotide Prodrug - NEW HAVEN, Conn., April 30, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that is has begun dosing study participants with ACH-3422, Achillion's proprietary uridine-analog nucleotide inhibitor, in a Phase 1 clinical trial.
Sign-up for Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, for HCV investment picks
MDX produced statistically significant improvement (p < 0.01) on the primary endpoint compared to placebo MDX was superior to placebo after a single dose while demonstrating a safety profile comparable to placebo Second placebo-controlled Phase II study in adults with ADHD to demonstrate the efficacy and tolerability of MDX NEW YORK, May 5, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd.
Sign-up for Alcobra Ltd. Presents Positive Results From Phase IIb Study of Metadoxine Extended Release (MDX) in Adults With Predominantly Inattentive ADHD at APA Annual Meeting investment picks
NEW YORK, May 13, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company has signed an exclusive license agreement with China-based Cellular Biomedicine Group (OTCQB:CBMG) ("CBMG") to begin a Phase 2 clinical trial in patients with late stage liver cancer.
Sign-up for NeoStem Announces Licensing Agreement and Plans to Begin Phase 2 Hepatocellular Carcinoma Trial in China investment picks
NEWARK, Calif., May 19, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Armin Curt, M.D., study principal investigator, presented an interim update on the Phase I/II trial in spinal cord injury at the Annual Meeting of the American Spinal Injury Association in San Antonio, Texas.
Sign-up for StemCells, Inc. Provides Update on Its Phase I/II Study in Spinal Cord Injury investment picks
Third Phase 3 Trial of Custirsen to Receive FDA Fast Track Designation BOTHELL, Wash.
Sign-up for OncoGenex Announces Fast Track Designation Granted for Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Phase 3 AFFINITY Trial of Men with Metastatic Castrate-Resistant Prostate Cancer investment picks
SOLANA BEACH, Calif., April 28, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) , a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that data from the Company's Phase 2b clinical trial of EVK-001, a novel intranasal formulation and delivery method of metoclopramide for diabetic female patients with symptoms associated with gastroparesis, was accepted for an oral presentation at Digestive Disease Week 2014 (DDW). DDW will take place May 3-6, 2014 in Chicago, Illinois.
Sign-up for Evoke Pharma Announces That EVK-001 Phase 2b Results Will be Presented at Digestive Disease Week 2014 investment picks
2014/5/1
MM-398 in combination with 5-fluorouracil and leucovorin demonstrates statistically significant advantage compared to control arm Plan to submit New Drug Application in 2014 Conference Call Scheduled for 8:30 a.m. ET Today CAMBRIDGE, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin achieved an overall survival of 6.1 months, a 1.9 month improvement over the 4.2 month survival demonstrated by the control arm of 5-FU and leucovorin alone.
Sign-up for Merrimack Pharmaceuticals Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer investment picks
Achieved Primary Endpoint of Complete Response (CR) in the Delayed Period (24 to 120 Hours) Following Initiation of Chemotherapy Achieved Key Secondary Endpoints of CR in the Acute and Overall Periods Achieved All Secondary Endpoints, Including No Significant Nausea Adverse Event Profile Consistent with Earlier Clinical Trials New Drug Application (NDA) Submission to U.S. FDA On Track for Mid-2014 WALTHAM, Mass., May 12, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) , an oncology-focused biopharmaceutical company, today announced positive top-line results from the third and final Phase 3 trial of rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV). The rolapitant arm in this trial, which enrolled patients receiving cisplatin-based, highly emetogenic chemotherapy (HEC), successfully achieved statistical significance over the standard
Sign-up for TESARO Announces Successful Achievement of Primary and All Secondary Endpoints in Third and Final Phase 3 Trial of Rolapitant investment picks
FDA's clearance of RedHill's Investigational New Drug ("IND") amendment allows the initiation of a Phase III clinical study for a new undisclosed indication with RHB-102 1 , a proprietary, once-daily, extended release oral pill formulation of the antiemetic drug ondansetron In parallel to pursuing the new undisclosed indication, RedHill is pursuing marketing approval of RHB-102 for the indications of chemotherapy and radiotherapy-induced nausea and vomiting ("CINV" and "RINV" respectively) in Europe and the U.S. TEL-AVIV, Israel, May 22, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd.
Sign-up for RedHill Biopharma Announces FDA Clearance for Phase III Study With RHB-102 Planned to Commence in Q3/2014 investment picks
Tufts University will be a clinical site for international trial of CF102 with Orphan Drug Designation PETACH TIKVA, Israel , April 29, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd.
Sign-up for Can-Fite Submits Protocol to U.S. FDA for Phase II Liver Cancer Study investment picks
REDWOOD CITY, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) , a biopharmaceutical company, today announced topline results from its Phase 1 onset-of-action study of patiromer, the final clinical trial planned to support a New Drug Application (NDA), which the company expects to submit to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
Sign-up for Relypsa Announces Topline Results From Patiromer Phase 1 Onset-of-Action Study investment picks
NEWARK, Calif., April 21, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) , today announced positive data from its Phase 1/2 study of RT002 injectable botulinum toxin type A for the treatment of moderate to severe glabellar (frown) lines.
Sign-up for Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lines investment picks
Vitaros ® National Phase Approval Process in Europe Completed SAN DIEGO, April 24, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI) , a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the Spanish Agency for Medicines and Health Products (AEMPS) has granted national phase approval to Vitaros ® , Apricus' novel topical on-demand treatment for erectile dysfunction ("ED"). With the approval in Spain, the Company has now received a total of ten national phase approvals for Vitaros ® , including Luxembourg, Belgium, France, Germany, Ireland, Italy, the Netherlands, Sweden and the United Kingdom (the "U.K.") following its broad approval by European health authorities in June 2013.
Sign-up for Apricus Biosciences Announces National Phase Approval for Vitaros(R) in Spain investment picks
NATICK, Mass., April 29, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) , a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in patients with glioblastoma following treatment with radiation and temozolomide.
Sign-up for Phase 2 Study of Selinexor (KPT-330) Initiated by Karyopharm in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide (KING Study) investment picks
NEW YORK, April 29, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) , a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has completed the enrollment of its OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age related macular degeneration ("wet-AMD"). The study has enrolled a total of 142 patients, and the Company expects to announce interim data on the first 60 patients completing the protocol in June this year.
Sign-up for Ohr Pharmaceutical Announces Completion of Enrollment in Phase II Clinical Trial of Squalamine Eye Drops in Wet-AMD investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Research Phase
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Permit  |  Next: Research Pipeline